A nomogram to predict pathologic T2 stage in candidates to robot-assisted radical prostatectomy with iT3 prostate cancer on preoperative multiparametric MRI: results from a multi-institutional collaboration.


Journal

Minerva urology and nephrology
ISSN: 2724-6442
Titre abrégé: Minerva Urol Nephrol
Pays: Italy
ID NLM: 101777299

Informations de publication

Date de publication:
Apr 2023
Historique:
medline: 3 4 2023
pubmed: 27 10 2022
entrez: 26 10 2022
Statut: ppublish

Résumé

In candidates to robot-assisted radical prostatectomy (RARP) for locally advanced (iT3) prostate cancer on preoperative MRI, the performance of MRI for local staging is demonstrably suboptimal, and currently no prediction tools that might help surgeons in preoperative planning are available. We analyzed data of 685 patients with iT3 prostate cancer (PCa) who received RARP at five participating institutions between 2012 and 2020. Multivariable logistic regression model investigated predictors of pT2 disease among variables available before surgery (i.e.: preoperative PSA, biopsy ISUP group, clinical T stage on digital rectal examination-DRE, prostate volume on MRI, PIRADS score of index lesion, seminal vesicles invasion on MRI, location suspicious for T3 disease on MRI). Coefficients from such model were used to build a nomogram to predict organ-confined (i.e. pT2) disease on final pathology. Internal validation was performed using the leave-one-out cross-validation. Median (interquartile range) preoperative PSA was 7.5 (5.2, 11.9) ng/mL, and 280 (41%) and 216 (32%) had biopsy ISUP group 4-5 disease and palpable disease on DRE, respectively. Preoperative MRI was suspicious for iT3 disease on the mid-posterior part of the gland in 485 (71%) men, and 527 (77%) men had a PIRADS 5 lesion. After surgery, a total of 192 (28%) patients had organ-confined disease (i.e. pT2). All variables fitted into the model and were considered to build the nomogram. After internal validation, the AUC was 73% (95% confidence interval: 69%, 77%). Awaiting external validation, we provided data that is relevant to optimize surgical strategy in men diagnosed with iT3 PCa who are scheduled for RARP.

Identifiants

pubmed: 36286397
pii: S2724-6051.22.04992-8
doi: 10.23736/S2724-6051.22.04992-8
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

231-234

Auteurs

Carlo A Bravi (CA)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium - carloandrea.bravi@gmail.com.
ORSI Academy, Ghent, Belgium - carloandrea.bravi@gmail.com.
Unit of Urology, Division of Oncology, IRCCS San Raffaele Hospital, Milan, Italy - carloandrea.bravi@gmail.com.

Elio Mazzone (E)

Unit of Urology, Division of Oncology, IRCCS San Raffaele Hospital, Milan, Italy.

Paolo Dell'oglio (P)

Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Department of Urology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Interventional Molecular Imaging Laboratory, Department of Radiology, University Medical Center of Leiden, Leiden, the Netherlands.

Marcio Covas Moschovas (M)

AdventHealth Global Robotics Institute, Celebration, FL, USA.

Alberto Martini (A)

Unit of Urology, Division of Oncology, IRCCS San Raffaele Hospital, Milan, Italy.

Giuseppe Rosiello (G)

Unit of Urology, Division of Oncology, IRCCS San Raffaele Hospital, Milan, Italy.

Pietro Piazza (P)

ORSI Academy, Ghent, Belgium.
Division of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.

Angelo Mottaran (A)

ORSI Academy, Ghent, Belgium.
Division of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.

Marco Paciotti (M)

ORSI Academy, Ghent, Belgium.
Department of Urology, Humanitas IRCCS Research Hospital, Rozzano, Milan, Italy.

Luca Sarchi (L)

ORSI Academy, Ghent, Belgium.
Department of Urology, University of Modena and Reggio Emilia, Modena, Italy.

Stefano Puliatti (S)

ORSI Academy, Ghent, Belgium.
Department of Urology, University of Modena and Reggio Emilia, Modena, Italy.

Sophie Knipper (S)

ORSI Academy, Ghent, Belgium.
Martini-Klinik Prostate Cancer Center, University Hospital of Hamburg-Eppendorf, Hamburg, Germany.

Ruben DE Groote (R)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.

Riccardo Schiavina (R)

Division of Urology, IRCCS University Hospital of Bologna, Bologna, Italy.

Bernando Rocco (B)

Department of Urology, Humanitas IRCCS Research Hospital, Rozzano, Milan, Italy.
Unit of Urological, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy.

Antonio Galfano (A)

Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Alberto Briganti (A)

Unit of Urology, Division of Oncology, IRCCS San Raffaele Hospital, Milan, Italy.

Francesco Montorsi (F)

Unit of Urology, Division of Oncology, IRCCS San Raffaele Hospital, Milan, Italy.

Vipul Patel (V)

AdventHealth Global Robotics Institute, Celebration, FL, USA.

Alexandre Mottrie (A)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH